SynthesisJournal of Alzheimer's disease reports2024
Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review.
Synthesis in Journal of Alzheimer's disease reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.Nature medicine · 2025Trial
- Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts.Alzheimer's research & therapy · 2026Article
- A digital twin methodology using retrospective patient data for sample size reduction in Alzheimer's disease clinical trials.Alzheimer's research & therapy · 2026Article
- Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts.Research square · 2026Article
- Diagnostic Blood-Based Biomarkers of Amyloid-β and Tau Pathologies Prior to Alzheimer's Disease Diagnosis: a Rapid Umbrella Review.SN comprehensive clinical medicine · 2026Review
- Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data.Alzheimer's research & therapy · 2025Article
- Diagnostic and prognostic multimodal prediction models in Alzheimer's disease: A scoping review.Journal of Alzheimer's disease : JAD · 2025Article
- A digital twin methodology using real patient data for sample size reduction in Alzheimer's disease randomized controlled clinical trials.medRxiv : the preprint server for health sciences · 2025Article
- Prognostic value of light reflex pupillometry in Alzheimer's disease - a longitudinal cohort study.Alzheimer's research & therapy · 2025Article
- Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Machine learning-based risk prediction model for cognitive dysfunction in elderly individuals.PloS one · 2025Article
- Color Fundus Photography and Deep Learning Applications in Alzheimer Disease.Mayo Clinic proceedings. Digital health · 2024Article
- Senolytic therapy preserves blood-brain barrier integrity and promotes microglia homeostasis in a tauopathy model.Neurobiology of disease · 2024Article
- Short-term data suggests cognitive benefits in the elderly with single-implant overdentures.Evidence-based dentistry · 2024Article
- Individualized and Biomarker-Based Prognosis of Longitudinal Cognitive Decline in Early Symptomatic Alzheimer's Disease.Journal of Alzheimer's disease reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 6 countries.
Funding
Abstract
Background: Alzheimer's disease (AD) causes progressive decline of cognition and function. There is a lack of systematic literature reviews on prognostic and predictive factors in its early clinical stages (eAD), i.e., mild cognitive impairment due to AD and mild AD dementia. Objective: To identify prognostic factors affecting eAD progression and predictive factors for treatment efficacy and safety of approved and/or under late-stage development disease-modifying treatments. Methods: Databases were searched (August 2022) for studies reporting prognostic factors associated with eAD progression and predictive factors for treatment response. The Quality in Prognostic Factor Studies tool or the Cochrane risk of bias tool were used to assess risk of bias. Two reviewers independently screened the records. A single reviewer performed data extraction and quality assessment. A second performed a 20% check. Content experts reviewed and interpreted the data collected. Results: Sixty-one studies were included. Self-reporting, diagnosis definition, and missing data led to high risk of bias. Population size ranged from 110 to 11,451. Analyses found data indicating that older age was and depression may be associated with progression. Greater baseline cognitive impairment was associated with progression. Conclusions: Age was the strongest risk factor for progression. Biomarkers were associated with progression, supporting their use in trial selection and aiding diagnosis. Baseline cognitive impairment was a prognostic factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.